Drugs / PRN1008
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02704429 | Jan 2016 → Dec 2019 | pemphigus vulgaris | Principia Biopharma, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRN1008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02704429 ↗ |
| Action | Inhibit | “BTK inhibitor” NCT02704429 ↗ |
| Route | Oral | “Oral Treatment With the BTK Inhibitor PRN1008” NCT02704429 ↗ |
| Target | BTK | “BTK inhibitor” NCT02704429 ↗ |